Pfizer Inc. (PFE)
| Market Cap | 174.36B |
| Revenue (ttm) | 55.09B |
| Net Income (ttm) | -309.00M |
| Shares Out | 5.67B |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | 12.22 |
| Dividend | $1.68 (5.46%) |
| Ex-Dividend Date | Jul 26, 2024 |
| Volume | 30,490,635 |
| Open | 30.15 |
| Previous Close | 29.76 |
| Day's Range | 30.01 - 30.88 |
| 52-Week Range | 25.20 - 37.19 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 34.50 (+12.12%) |
| Earnings Date | Jul 30, 2024 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and po... [Read more]
Financial Performance
In 2023, Pfizer's revenue was $58.50 billion, a decrease of -41.70% compared to the previous year's $100.33 billion. Earnings were $2.12 billion, a decrease of -93.25%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $34.5, which is an increase of 12.12% from the latest price.
News
Will Pfizer Stock Post A Downbeat Q2?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $12.95 billion and earnings of $0.44 on a per share and adjusted basis, lowe...
Final Trades: Freeport-McMoran, Pfizer, Danaher and United Rentals
The Investment Committee give you their top stocks to watch for the second half.
European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene t...
These three stocks could help you AI-proof your portfolio
Gina Sanchez, CEO of Chantico Global, discusses how to protect your portfolio from increased volatility and the run-up in AI stocks.
UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant
Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adult...
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.
Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could be...
Pfizer's hemophilia A gene therapy found superior to current treatment in late-stage trial
Pfizer said on Wednesday that its gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better t...
Pfizer announces positive results from late-stage trial of Hemophilia A treatment
Pfizer Inc. PFE, -0.34% announced positive results Wednesday from a late-stage trial of a gene therapy as a treatment for adults with moderately severe to severe Hemophilia A. The Phase 3 trial called...
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene ...
XOM, PFE, CMCSA: Opportunities in International & Emerging Markets
Markets are grappling with uncertainty on the recently prevailing narratives, notes David Dietze. He talks about finding opportunities in international and emerging markets.
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
On Wednesday, Pfizer Inc PFE and Valneva SE VALN announced that the participants of the Phase 3 VALOR trial have completed the primary vaccination series (three doses) of Lyme disease vaccine candidat...
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc PFE, one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the participants of the Phase 3 trial “Vaccine...
Trade Tracker: Josh Brown gets stopped out of Sharkninja and Pfizer hits its highest level of 2024
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to discuss his latest trade out of Sharkninja, and how he's thinking about Pfizer at these levels.
Final Trades: Cisco Systems, Arch Capital, Pfizer, and the COWZ
The Investment Committee give you their top stocks to watch for the second half.
Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason
Israel's CytoReason, which uses AI to develop disease models, said on Wednesday it had raised $80 million in a private funding round.
European Commission didn't provide enough information about COVID-19 vaccine deals, EU court says
The European Commission did not allow the public enough access to information about COVID-19 vaccine purchase agreements it secured with pharmaceutical companies during the pandemic, the EU general co...
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Thursday, Pfizer Inc PFE announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.
Pfizer moves forward with once-daily weight-loss pill to compete with Wegovy
Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday.
Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk what impact, if any, the Pfizer weight-loss drug trial will have on the stock.
Pfizer moves forward with once-daily version of weight-loss pill after setbacks
Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw “encouraging” data in an ongoing early-stage study.
Three-Stock Lunch: Apple, Pfizer and Delta Air Lines
Michael Farr, Hightower Advisors chief investment strategist, joins 'Power Lunch' to discuss stock plays for three stocks.
Final Trades: Pfizer, L3Harris Tech, the RSP and GDX
The Investment Committee give you their top stocks to watch for the second half.
Pfizer Stock Rises as Company Advances Studies of Once-a-Day Weight-Loss Pill
Shares of Pfizer (PFE) advanced as the drug maker announced that it was moving forward with research into a potential once-a-day weight-loss pill.